UCART19 ΔCD2

UCART19 ΔCD2 is a research-grade, allogeneic chimeric antigen receptor (CAR) T-cell product derived from UCART19. It is engineered to target the CD19 antigen while featuring dual genetic deletions of the T-cell receptor alpha chain (TRAC), to prevent graft-versus-host disease (GvHD), and the CD2 co-stimulatory receptor. Developed primarily as a research tool to investigate the role of the CD2:CD58 axis in CAR-T cell potency, studies have shown that the absence of CD2 leads to impaired immunological synapse formation, reduced secretion of effector cytokines such as Granzyme-B and IFN-γ, and significantly attenuated anti-tumor efficacy in xenograft models compared to standard UCART19. While the parent product UCART19 is a clinical candidate for B-cell malignancies, UCART19 ΔCD2 serves to highlight the importance of CD2 co-stimulation in maintaining CAR-T cell functionality.

Other names

CD2-deleted UCART19CD-2-deleted UCART19CD 2-deleted UCART19UCART19 delta CD2UCART-19 delta CD2UCART 19 delta CD2